Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted ...
— If approved, would confirm 2021 conditional approval and expand indication to more patients — HUTCHMED (China) Lim...
cTTP, an ultra-rare blood clotting disorder, presents life-threatening acute events and debilitating chronic symptoms. Untreated acute TTP ...
Johnson & Johnson has announced the approval of OPSYNVI® by the U.S. Food and Drug Administration (FDA), marking a significant advanc...
“We are thrilled with the positive CHMP opinion, which reflects the significant cardiovascular risk reduction benefit that the bemped...
• The agreement furthers Hovione´s ability to bring the benefits of continuous tableting, including reduced time to market and in...
Optinose, a pharmaceutical company specializing in treatments for ear, nose, and throat (ENT) and allergy conditions, has achieved a significant milestone ...
Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI®, the first and only approved therapy in the Europea...
The newly granted patent enriches Salipro Biotech's comprehensive intellectual property (IP) portfolio, securing its method for stabilizing challenging dru...
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company specializing in endocrine diseases and tumors, revealed encouraging...
Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneous...
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis Late-breaking dat...
BRUKINSA is the first and only BTK inhibitor approved across five oncology indications and the first and only approved in follicular lymphoma Approv...
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced...
© 2025 Biopharma Boardroom. All Rights Reserved.
